Skip to main content

Table 1 Active clinical trials of novel therapeutic agents for RRMM presented at major oncology meetings, 2019–2020

From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Antigen Product name* (NCT) Study sponsor Estimated enrollment Country Clinical Update reference
CAR-T cells      
BCMA JNJ-68284528 (NCT03548207) Janssen 118 United States, Japan 2020 ASH [7]
BCMA bb21217 (NCT03274219) Bluebird 74 United States 2020 ASH [8]
NY-ESO-1 GSK3377794 (NCT03168438) GlaxoSmithKline 20 United States 2019 ASH [9]
BCMA /CD19 GC012F (NCT04236011) Shanghai Changzheng Hospital 15 China 2020 ASH [10]
BCMA/CD38 BM 38CAR (ChiCTR1800018143) Wuhan Tongji Medical College Union Hospital 20 China 2019 ASH [11]
BCMA ALLO-715 (NCT04093596) Allogene 90 United States 2020 ASH [12]
Bispecific antibody (BiTE)      
BCMA × CD3 Teclistamab JNJ-64007957 (NCT03145181) Janssen 160 United States, the Netherlands, Spain, Sweden 2020 ASH [13]
BCMA × CD3 CC-93269 (NCT03486067) Celgene 115 United States, Spain 2019 ASH [14]
BCMA × CD3 PF-06863135 (NCT03269136) Pfizer 80 United States, Canada 2020 ASH [15]
BCMA × CD3 TNB-383B (NCT03933735) Tenebio AbbVie 72 United States 2020 ASH [16]
BCMA × CD3 REGN5458 (NCT03761108) Regeneron 74 United States, Belgium 2020 ASH [17]
GPRC5D × CD3 Talquetamab JNJ-64407564 (NCT03399799) Janssen 245 United States, Netherlands, Spain 2020 ASH [18]
FcRH5 × CD3 BFCR4350A (NCT03275103) Genentech 300 United States, Australia, Canada, Spain 2020 ASH [19]
Antibody–drug conjugate (ADC)      
BCMA, pyrrolobenzodiazepine MEDI2228 (NCT03489525) MedImmune 142 United States, Australia, Greece 2020 ASH [20]
BCMA, Shiga-like toxin-A subunit (engineered toxin bodies) TAK-169 (NCT04017130) Millennium Takeda 102 United States 2019 ASH [21]
Monoclonal antibody (MoAb)      
CD38 TAK-079 (NCT03439280) Millennium Takeda 100 United States 2020 ASCO [22]
CD38 with interferon TAK-573 (NCT03215030) Millennium Takeda 151 United States 2020 ASH [23]
CD38 SAR442085 (NCT04000282) Sanofi 78 United States, France, Spain 2020 AACR[24]
Small molecule inhibitors and modulators      
BCL-2 inhibitor Venetoclax (NCT03314181, NCT01794520) AbbVie 104, 117 United States, Australia, Belgium, Canada, Denmark, France, Germany, Norway 2019 ASH [25], 2019 ASH [26]
BCL-2 inhibitor AT-101 (NCT02697344) Mayo Clinic 10 United States 2019 ASH [27]
HDAC inhibitor Alteminostat (NCT03150316) Chong Kun Dang Pharamaceutical 18 South Korea 2019 ASH [28]
HDAC inhibitor Chidamide (NCT04025450) The First Affiliated Hospital of Soochow University 50 (high-risk NDMM) China 2019 ASH [29]
Cereblon E3 ligase modulator Iberdomide (CC-220) (NCT02773030) Celgene 449 United States, France, Germany, Italy, Japan, the Netherlands, Spain, United Kingdom 2020 ASH [30]
Cereblon E3 ligase modulator CC-92480 (NCT03374085) Celgene 80 United States, Canada, Denmark, Finland, Spain, United Kingdom 2020 ASH [31]
MEK inhibitor Cobimetinib (NCT03312530) Hoffmann-La Roche 72 Czechia, Denmark, France, Germany, Netherlands, Norway, Poland, Spain, Sweden 2020 ASH [32]
MEK and BRAF inhibitors Encorafenib and binimetinib (NCT02834364) University of Heidelberg 12 Germany 2020 ASH [33]
Other therapies      
Peptidase enhanced cytotoxic Melflufen (NCT03481556) Oncopeptides 80 United States, Czechia, Spain 2020 ASH [34]
Peptidase enhanced cytotoxic Melflufen (NCT02963493) Oncopeptides 157 United States, France, Italy, Spain 2020 ASCO [35]
  1. ASCO American Society of Clinical Oncology, ASH American Society of Hematology, AACR American Association for Cancer Research
  2. *In cases where no unique product name was given, only the NCT number is listed to the bottom of the table (see Table 2 for example)